Important Short Interest Filing: What Will Happen to TAXUS CARDIUM PHARMA (OTCMKTS:CRXM) Next? The Stock Has Increase in Shorts

November 30, 2016 - By Peter Erickson   ·   0 Comments

Important Short Interest Filing: What Will Happen to TAXUS CARDIUM PHARMA (OTCMKTS:CRXM) Next? The Stock Has Increase in Shorts

The stock of TAXUS CARDIUM PHARMA (OTCMKTS:CRXM) registered an increase of 27.78% in short interest. CRXM’s total short interest was 2,300 shares in November as published by FINRA. Its up 27.78% from 1,800 shares, reported previously. With 34,000 shares average volume, it will take short sellers 0 days to cover their CRXM’s short positions. About 100 shares traded hands. Taxus Cardium Pharmaceuticals Group Inc (OTCMKTS:CRXM) has 0.00% since April 27, 2016 and is . It has underperformed by 5.23% the S&P500.

Taxus Cardium Pharmaceuticals Group, Inc. is a holding company. The company has a market cap of $2.45 million. The Firm operates a medical technologies portfolio of investments, which include Angionetics, Inc. , Activation Therapeutics, Inc., To Go Brands, Inc. and LifeAgain Insurance Solutions, Inc. (LifeAgain). It currently has negative earnings. Angionetics is focused on the late-stage clinical development and commercialization of Generx (Ad5FGF-4), an angiogenic gene therapy product candidate.

CRXM Company Profile

Taxus Cardium Pharmaceuticals Group, Inc., incorporated on December 22, 2003, is a holding company. The Firm operates a medical technologies portfolio of investments, which include Angionetics, Inc. (Angionetics), Activation Therapeutics, Inc., To Go Brands, Inc. and LifeAgain Insurance Solutions, Inc. (LifeAgain). Angionetics is focused on the late-stage clinical development and commercialization of Generx (Ad5FGF-4). Ad5FGF-4 is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. Generx addresses an unmet medical need for patients with refractory angina who are no longer responsive to maximally tolerated medical therapy, and are not candidates for, and would receive no prophylactic therapeutic benefit from, percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). Ad5FGF-4 consists of human adenovirus serotype-5 (Ad5) that has been modified to express the human fibroblast growth factor-4 (FGF-4) gene driven by a cytomegalovirus (CMV) promoter.

More notable recent Taxus Cardium Pharmaceuticals Group Inc (OTCMKTS:CRXM) news were published by: Marketwatch.com which released: “Taxus Cardium Pharmaceuticals Group Inc.” on January 31, 2014, also Prnewswire.com with their article: “Cardium Becomes Taxus Cardium Pharmaceuticals Group In Connection With …” published on March 17, 2014, Prnewswire.com published: “Taxus Cardium Announces Agreement With Dr. Reddy’s Laboratories To Co-Develop …” on April 07, 2015. More interesting news about Taxus Cardium Pharmaceuticals Group Inc (OTCMKTS:CRXM) were released by: Businesswire.com and their article: “Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene …” published on August 13, 2014 as well as Prnewswire.com‘s news article titled: “Taxus Cardium’s Excellagen® Selected For Use With Stem Cells In European Union …” with publication date: May 12, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Peter Erickson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>